Katie Insogna

Partner

CO-CHAIR, PHARMACEUTICAL AND MEDICAL DEVICE PRODUCT LIABILITY SUB-PRACTICE GROUP

katie.insogna@dlapiper.com

Boston

T: +1 617 406 6046

F: +1 617 406 6183

Katie Insogna's practice focuses on the defense of pharmaceutical, life science and medical device companies in a variety of cases, including multidistrict product liability litigation and complex commercial litigation.

- Litigation, Arbitration and Investigations

Katie has extensive expertise with fact and expert witness development, discovery and dispositive motion practice, and trial preparation. Katie has taken and defended numerous party and third-party witness depositions in product liability and commercial litigation cases. She also has argued motions in state and federal courts.

Admissions

- California
- Massachusetts

Recognitions

- *The Legal 500 United States*
  - 2022 - Next Generation Partner, Healthcare: Life Sciences
  - 2022 - Next Generation Partner, Dispute Resolution Product Liability, Mass Tort and Class Action - Defense: Pharmaceuticals and Medical Devices
  - 2021 - Next Generation Partner, Healthcare: Life Sciences
  - 2021 - Next Generation Partner, Dispute Resolution Product Liability, Mass Tort and Class Action: Pharmaceuticals and Medical Devices - Defense
  - 2020 - Rising Star, Healthcare: Life Sciences
  - 2020 - Rising Star, Dispute Resolution Product Liability, Mass Tort and Class Action: Pharmaceuticals and Medical Devices - Defense

Education

- J.D., University of Southern California Gould School of Law 2009
- B.A., Psychology, Georgetown University 2006
  magna cum laude

Courts

- United States Court of Appeals for the Ninth Circuit
- United States District Court for the Central District of California
- United States District Court for the District of Massachusetts
- United States District Court for the Northern District of California
- United States District Court for the Southern District of California

Externship Experience

During law school, Katie externed for the Honorable Valerie Baker Fairbank, United States District Court for the Central District of California.

INSIGHTS

Publications

FDA warning letters: More warnings and closer scrutiny of COVID-19 and vaping products

26 April 2021
A large percentage of warning letters concern adulterated, unapproved or misbranded products related to COVID-19, and e-cigarette companies continue to be in the agency's crosshairs for selling unapproved products.

- Author, "Successfully Positioning Litigation for an MDL," *American Bar Association*, March 18, 2022
- Author, "FDA Q2 Warning Letters Show Agency Enforcement Priorities," *Law360*, July 19, 2021
- Author, "FDA Letters Suggest Scrutiny Of Virus And Vaping Products," *Law360*, April 8, 2021
- Author, "Massachusetts Supreme Court recognizes brand-name pharmaceutical makers owe duty to consumers of generic medications," *DLA Piper*, March 19, 2018
- Co-Author, "Plaintiff Fact Sheets In Mass Tort Discovery: Keys To Success," *Law360*, September 22, 2021